2 results
Approved WMOCompleted
Phase 1b:Primary:- To evaluate the safety and tolerability and determine the recommended Phase 2 dose (RP2D) and schedule of ALRN-6924 when administered to patients with TP53-mutated extensive disease (ED) small cell lung cancer (SCLC) receiving…
Approved WMOCompleted
The primary objective is to evaluate the pharmacokinetic (PK) parameters of JNJ-63623872 in combination with oseltamivir in elderly subjects (aged 65 to *85 years) compared to adults (aged 18 to *64 years) with influenza A infection.